Home » Topics » BioWorld Science

BioWorld Science
RSS

Merck & Co.'s rVSV-ZEBOV Ebola vaccine deployed in Democratic Republic of Congo

May 22, 2018

FDA accepts NDA for Rifamycin SV MMX

May 22, 2018

KRAS-G12C inhibitors reveal new approach to undruggable targets

May 22, 2018

FDA approves Lokelma for hyperkalemia

May 22, 2018

New anticancer adaptive cell therapy approach as cancer immunotherapeutic shows promise

May 22, 2018

Lundbeck begins clinical development with PDE1 inhibitor Lu-AF-76432

May 22, 2018

Prolia approved in U.S. for glucocorticoid-induced osteoporosis

May 22, 2018

FDA awards breakthrough therapy and fast track designations to Harmony's pitolisant

May 22, 2018

European Commission approves Juluca for HIV-1

May 22, 2018

FDA approves thrombopoietin receptor agonist Doptelet

May 22, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 5, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...